<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593277</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121029</org_study_id>
    <secondary_id>NCI-2020-04792</secondary_id>
    <secondary_id>10470</secondary_id>
    <secondary_id>U01CA246659</secondary_id>
    <nct_id>NCT04593277</nct_id>
  </id_info>
  <brief_title>Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study</brief_title>
  <official_title>INSPIRE-AYA: A Multicenter Interactive Survivorship Program to Improve Healthcare Resources for Adolescent and Young Adult (AYA) Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well an interactive survivorship program works in improving healthcare&#xD;
      resources in adolescent and young adult cancer survivors. By improving access to survivorship&#xD;
      resources, health literacy, self-management skills, and support, an interactive survivorship&#xD;
      program may help to improve adherence to adolescent and young adult healthcare guidelines and&#xD;
      reduce cancer-related distress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients who have one or more elevated distress or low cardiometabolic or cancer&#xD;
      health care adherence are randomized to Arm I or II. Patients who do not have elevated&#xD;
      distress or low cardiometabolic or cancer health care adherence are assigned to Group 0.&#xD;
&#xD;
      ARM I (INTERVENTION): Patients receive a personalized smart cell phone (SCP) and use the&#xD;
      Interactive Survivorship Program to Improve Healthcare Resources (INSPIRE) mobile&#xD;
      application. Patients may receive telehealth stepped care after 1 month.&#xD;
&#xD;
      ARM II (CONTROL): Patients receive access to a study-specific control website that has&#xD;
      annotated links to existing resources for adolescent and young adult (AYA) survivors. After&#xD;
      12 months, patients receive a personalized SCP and have access to the digital INSPIRE&#xD;
      intervention program without telehealth calls.&#xD;
&#xD;
      GROUP 0: Patients have access to the digital INSPIRE program and receive printed SCP&#xD;
      materials without telehealth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distress score (3 months)</measure>
    <time_frame>At 3 months</time_frame>
    <description>Will be assessed by Cancer and Treatment Distress (CTXD). Patients will meet the primary endpoint for lack of distress if they score &lt; 0.9 on the CTXD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distress score (12 months)</measure>
    <time_frame>At 12 months</time_frame>
    <description>Will be assessed by Cancer and Treatment Distress (CTXD). Patients will meet the primary endpoint for lack of distress if they score &lt; 0.9 on the CTXD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of healthcare adherence (HCA)-all</measure>
    <time_frame>At 12 months</time_frame>
    <description>Patients will meet HCA endpoint if their percent of recommended screenings obtained within the past 12 months is &gt;= 80% for HCA-all.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HCA-cardiometabolic surveillance (CM)</measure>
    <time_frame>At 12 months</time_frame>
    <description>Patients will meet each HCA endpoint if their percent of recommended screenings obtained within the past 12 months is &gt;= 80% for HCA-CM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HCA-cancer surveillance (SM)</measure>
    <time_frame>At 12 months</time_frame>
    <description>Patients will meet each HCA endpoint if their percent of recommended screenings obtained within the past 12 months is &gt;= 80% for HCA-SM.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Clinical Stage I Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IA Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IB Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage II Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IIA Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IIB Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IIC Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage III Cutaneous Melanoma AJCC v8</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Invasive Malignant Neoplasm</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Pathologic Stage I Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IA Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IB Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage II Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIA Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIB Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIC Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage III Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIIA Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIIB Cutaneous Melanoma AJCC v8</condition>
  <condition>Pathologic Stage IIIC Cutaneous Melanoma AJCC v8</condition>
  <condition>Sarcoma</condition>
  <condition>Stage I Colorectal Cancer AJCC v8</condition>
  <condition>Stage II Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIC Colorectal Cancer AJCC v8</condition>
  <condition>Stage III Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIIA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIIB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIIC Colorectal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (INSPIRE, telehealth care)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a personalized SCP and use the INSPIRE mobile application. Patients may receive telehealth stepped care after 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (control website)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 0 (INSPIRE, printed material)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients have access to the digital INSPIRE program and receive printed SCP materials without telehealth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Informational Intervention</intervention_name>
    <description>Receive printed SCP materials</description>
    <arm_group_label>Group 0 (INSPIRE, printed material)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Internet Mobile Technology</intervention_name>
    <description>Use INSPIRE mobile application</description>
    <arm_group_label>Arm I (INSPIRE, telehealth care)</arm_group_label>
    <arm_group_label>Group 0 (INSPIRE, printed material)</arm_group_label>
    <other_name>www-mobile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Internet-Based Intervention</intervention_name>
    <description>Access to a study-specific control website</description>
    <arm_group_label>Arm II (control website)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (INSPIRE, telehealth care)</arm_group_label>
    <arm_group_label>Arm II (control website)</arm_group_label>
    <arm_group_label>Group 0 (INSPIRE, printed material)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Supportive Care</intervention_name>
    <description>Receive telehealth stepped care</description>
    <arm_group_label>Arm I (INSPIRE, telehealth care)</arm_group_label>
    <other_name>Supportive Therapy</other_name>
    <other_name>Symptom Management</other_name>
    <other_name>Therapy, Supportive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with a first invasive malignancy of leukemia, lymphoma, colorectal cancer,&#xD;
             melanoma, or sarcoma (stage 1-3 for solid tumors) between the ages of 15-39 years&#xD;
&#xD;
          -  Currently within 1 to 5 years from the time of diagnosis&#xD;
&#xD;
          -  Completed active treatment for disease &gt;= 6 months previously&#xD;
&#xD;
          -  Received a therapeutic intervention (with curative intent if advanced stage disease)&#xD;
             that included any of the following modalities: surgery, cytotoxic chemotherapy,&#xD;
             biological or targeted agents, radiation therapy&#xD;
&#xD;
          -  English proficiency adequate to complete assessments&#xD;
&#xD;
          -  Access to email and smartphone mobile app and or internet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Development of an invasive subsequent malignancy other than non-melanoma skin cancer&#xD;
             in the past year or in active treatment for a subsequent malignancy&#xD;
&#xD;
          -  Health issues prohibiting computer use or ability to comply with study procedures&#xD;
&#xD;
          -  Residing in an institution or other living situation where health care decisions are&#xD;
             not made by the participant (e.g., hospitalized, prisoners, living in a rehabilitation&#xD;
             facility)&#xD;
&#xD;
          -  Does not complete baseline patient reported outcome (PRO) assessment items required to&#xD;
             determine stratification or whether the survivor meets inclusion and exclusion&#xD;
             criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Baker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheri Ballard</last_name>
    <phone>206.667.4222</phone>
    <email>sballard@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Patricia A. Ganz</last_name>
    </contact>
    <investigator>
      <last_name>Patricia A. Ganz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ann H. Partridge</last_name>
    </contact>
    <investigator>
      <last_name>Ann H. Partridge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Danielle N. Friedman</last_name>
    </contact>
    <investigator>
      <last_name>Danielle N. Friedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Linda Jacobs</last_name>
    </contact>
    <investigator>
      <last_name>Linda Jacobs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sheri Ballard</last_name>
      <phone>206-667-4222</phone>
      <email>sballard@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Baker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

